Target intelligence / Profile preview

High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) (FCER1A)

Target
FCER1A
Molecular classification
Receptor, Immunoglobulin superfamily
01

Overview

The High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) is a transmembrane protein that serves as the ligand-binding subunit of the high-affinity IgE receptor complex (UniProt P12319). It is predominantly expressed on mast cells and basophils, but also on professional antigen-presenting cells such as oral Langerhans cells (OLCs) (Allam et al., 2003, J Allergy Clin Immunol). In the oral mucosa, FcεRIα plays a pivotal role in capturing aeroallergens like Timothy grass pollen, cat dander, and house dust mites, facilitating their processing and presentation to the immune system (Novak et al., 2004, J Allergy Clin Immunol). This interaction is a cornerstone of the allergic response, leading to the release of pro-inflammatory mediators upon allergen cross-linking. Conversely, in the context of sublingual immunotherapy (SLIT), the receptor's activity on OLCs is essential for inducing mucosal tolerance and shifting the immune response from a Th2 to a Th1/Treg profile (Allam et al., 2008, Allergy). Drugs like Omalizumab target this pathway by sequestering free IgE, thereby preventing its binding to FcεRIα and downregulating the receptor's expression on cell surfaces (PubChem CID 16124778). By modulating the activity of FcεRIα on OLCs, clinicians can influence the success of sublingual immunotherapy (SLIT), which aims to induce immune tolerance rather than inflammation. Consequently, FcεRIα serves as both a critical mediator of allergic pathology and a strategic target for biological therapies designed to interrupt the IgE-mediated signaling cascade.

Other names
FCER1AFCE1AIgE receptor alpha subunitFc-epsilon RI-alphaHigh affinity immunoglobulin epsilon receptor alpha-subunit
02

Mechanism of action

Anti-IgE monoclonal antibodies bind to the Cε3 domain of circulating IgE, preventing its interaction with the FcεRIα subunit on the surface of immune cells, which leads to a reduction in receptor density and inhibition of allergen-induced activation (PubChem CID 16124778).

03

Biological functions

Immune responseAllergen presentationSignal transductionCell activation
04

Disease associations

AllergyAsthmaInflammationAtopic dermatitis
05

Safety considerations

AnaphylaxisInjection site reactionsPotential risk of parasitic infectionsMalignancy risk (theoretical/monitored)
06

Interacting drugs

Omalizumab

2 more in the full profile.

07

Biomarkers

Total serum IgEFcεRI expression on basophilsSpecific IgE levels

Beyond the preview

Go deeper on High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) (FCER1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on High affinity immunoglobulin epsilon receptor subunit alpha (FcεRIα) (FCER1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call